MannKind | MNKD - Cost Of Sales


MannKind reported $34.21M in Cost of Sales for its fiscal quarter ending in June of 2026.





Cost Of Sales Change Date
Adma Biologics USD 33.74M 16.65M Mar/2026
BioCryst Pharmaceuticals USD 3.84M 5.68M Jun/2026
Eli Lilly USD 3.27B 309M Jun/2026
Halozyme Therapeutics USD 108.68M 67K Jun/2026
Insmed USD 69.29M 19.79M Jun/2026
Karyopharm Therapeutics USD 1.34M 139K Mar/2026
MacroGenics USD 9.53M 585K Mar/2026
MannKind USD 34.21M 5.38M Jun/2026
Merck USD 3.14B 200M Jun/2026
Minerva Neurosciences 386K 31K Jun/2024
Novavax USD 22.1M 608K Dec/2025
Novo Nordisk DKK 2.66B 10.94B Jun/2026
Pfizer USD 4.09B 498M Jun/2026
Sanofi EUR 3.02B 656M Jun/2026
Xencor USD 61.66M 50.95M Jun/2025